Ergoteles’s AYTU BioPharma AYTU Stock Holding History

Ergoteles’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,774	Closed	-$378K	–	1213
2021 Q2	$378K	Buy	+3,774	New	+$443K	0.01%	943

Other funds holding AYTU

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's AYTU Position: Q3 2021 in Review

Ergoteles sold out of AYTU BioPharma (AYTU) in Q3 2021, closing a stake of 3,774 shares — an estimated $378K sold.

Ergoteles first reported a position in AYTU in Q2 2021 and held it in 1 quarter. The position peaked at $378K in Q2 2021. 39 funds tracked by Wall St. Rank hold AYTU as of Q3 2021.

Ergoteles reported no remaining AYTU BioPharma position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 3,774 AYTU BioPharma shares in Q3 2021, an estimated $378K.
Ergoteles first reported a position in AYTU BioPharma in Q2 2021 and held it in 1 quarter.
Ergoteles's AYTU BioPharma position peaked at $378K in Q2 2021.
39 funds tracked by Wall St. Rank held AYTU BioPharma as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.